How Much Does TB-500 Cost? (2026)

TB-500 generates a lot of cost searches, and for a predictable reason: the prices you see vary by a factor of ten or more depending on where and how you look. One search returns research-vendor vials under $50. Another returns clinic program quotes approaching $500 per month. Both are being called "TB-500." They are not selling the same product, and comparing their prices directly produces a meaningless number. The label is identical; what sits behind it is not.

This guide breaks down every pricing tier for TB-500, explains what determines the gap between them, covers the regulatory context that shapes what is legally available in 2026, and gives you the questions worth asking before spending anything. It does not tell you whether TB-500 is appropriate for your situation — that requires a conversation with a licensed physician who has access to your medical history.

To understand what TB-500 is and how it differs from the full-length protein, see our overview of what peptides are and how they work, and our TB-500 evidence review covering what the research actually shows.

The two markets for TB-500 — and why they price differently

TB-500 — formally thymosin beta-4 fragment (LKKTETQ), CAS number 77591-33-4 — is a synthetic 43-amino acid peptide. It is not approved by the FDA for any human therapeutic use. That single regulatory fact creates two parallel markets with fundamentally different economics.

The first is the gray market: online vendors who sell TB-500 labeled "for research use only," no prescription required, no physician involved, no licensed pharmacy in the supply chain. These sellers operate in a legal gray zone. Their prices are lower because they have removed the entire regulatory and medical layer from the transaction. What you receive is a compound. What you do not receive is a care pathway.

The second is the licensed clinical market: physicians who prescribe TB-500, which is then compounded by a state-licensed 503A pharmacy under physician supervision. This pathway is more expensive because the price includes a clinical evaluation, pharmacy compounding under USP sterility standards, quality testing, and an accountability structure. The premium reflects services rendered — not a more efficient supply of the same raw molecule.

Comparing prices across these two markets without recognizing this distinction produces meaningless comparisons. A $45 gray-market vial and a $200 compounded clinic vial are not cheaper and more expensive versions of the same product. They are different products with different risk profiles.

Gray-market (research-vendor) pricing

Research-peptide vendors sell TB-500 in vials ranging from 2 mg to 10 mg, at prices that vary substantially based on order size, vendor tier, and claimed quality level. Based on current market data, here is what the gray-market looks like in 2026:

• 5 mg vials, single purchase: $30 to $70 per vial at established online storefronts
• 10 mg vials, single purchase: $60 to $124 per vial depending on vendor and purity claims
• Per-milligram cost: $4.40 to $14 per mg — the wide range reflects vendor quality, batch testing, and whether cold-chain shipping is included
• Multi-vial kits: Larger kit orders typically reduce the per-mg cost by 15–30% compared to single-vial retail pricing
• Reconstitution supplies: Bacteriostatic water, insulin syringes, alcohol swabs, and a sharps container add approximately $15–$40 to the true first-purchase cost

These prices become less straightforward once you examine what they include. Third-party purity verification, sterility testing, cold-chain shipping, and a batch-specific certificate of analysis (CoA) are not standard across gray-market suppliers. The variance in actual product quality is substantial. When FDA reviewed the safety data for TB-500 as part of the 503A bulk drug substance nomination process, it documented that "compounded drugs containing thymosin Beta-4, Fragment (LKKTETQ) may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation as well as peptide-related impurities."²

Dr. Pieter Cohen, an associate professor of medicine at Harvard Medical School who has studied unregulated injectable compounds extensively, addressed the broader problem in a Harvard Health Publishing interview:

"When you're talking about peptides being promoted online, those health claims have not been vetted by any expert group, the FDA, or anyone else. The health claims are divorced from data." — Dr. Pieter Cohen, Associate Professor of Medicine, Harvard Medical School³

A cheaper research-vendor vial is not a neutral choice. The lower price typically describes what is absent from the manufacturing and verification chain, not a more efficient supply of equivalent material. Purity levels, sterility assurance, and dosing accuracy vary widely across gray-market batches, and there is no external check on the compounds you receive.

Clinic and compounding pharmacy pricing

When TB-500 is prescribed by a physician and compounded by a licensed 503A pharmacy, the economics look substantially different — and so does what you receive.

• Compounded TB-500 (5 mg), per-vial: $75 to $200 depending on pharmacy and geographic region
• Initial telehealth consultation: $150 to $400, typically billed at first evaluation
• Baseline lab work (if required by the prescribing physician): $100 to $250
• Monthly medication cost, mid-tier telehealth clinic: $120 to $300 per month
• Monthly medication cost, specialist practice: $175 to $450 per month
• First-month all-in cost at a specialist clinic: $425 to $1,100 including consultation, labs, and medication
• Follow-up visits: $75 to $200 per visit, typically quarterly

Many telehealth platforms bundle consultation, prescription management, and pharmacy dispensing under a single monthly fee — typically $150 to $350 per month once past the first-month intake cost. What that fee includes varies considerably from clinic to clinic. Some programs cover follow-up visits and protocol adjustments; others bill each encounter separately.

TB-500 price comparison by source type

Source	Per-vial cost (5 mg)	Monthly estimate	Physician involved	Purity verified
Gray-market online (no CoA)	$30–$50	$30–$100	No	Not verified
Gray-market online (with third-party CoA)	$50–$100	$50–$150	No	Supplier-claimed only
Mid-tier telehealth / med-spa clinic	Bundled	$120–$300	Yes	Third-party tested
Licensed 503A compounding pharmacy (specialist clinic)	$75–$200	$175–$450	Yes	Third-party tested
Telehealth bundled protocol (first month, all-in)	Bundled	$300–$1,100+	Yes	Third-party tested

What drives the price gap

Purity and independent testing

Research-grade TB-500 synthesis requires HPLC (high-performance liquid chromatography) analysis to confirm active peptide purity — typically 98 percent or above for active peptide content — and mass spectrometry to verify the correct molecular structure at 4,963.4 g/mol. Facilities like Janoshik and MZ Biolabs charge for this testing, and the cost is reflected in the final vial price. Gray-market suppliers vary widely in whether they test at all, whether testing is batch-specific, and whether the certificate of analysis comes from an independent laboratory. Purity shortfalls mean less active compound per vial and a higher proportion of synthesis byproducts whose effects in humans are not characterized.

Sterile manufacturing

Injectable peptide preparations require sterile manufacturing environments. State-licensed compounding pharmacies operate under USP Chapter 797 standards, which require cleanroom conditions, regular environmental monitoring, and end-product sterility testing. Gray-market operations face none of these regulatory requirements. There is no reliable external method for verifying manufacturing conditions from outside the facility.

Cold-chain shipping

Peptides degrade when exposed to heat. Proper cold-chain shipping — maintaining temperature between 2°C and 8°C from manufacturer to end recipient — adds $15 to $35 per order. Many gray-market vendors ship at ambient temperature with minimal insulation. A heat-degraded peptide vial looks identical to a properly stored one, and there is no visible indicator of potency loss.

Medical oversight

The licensed clinic premium includes physician evaluation of whether TB-500 is appropriate for a specific patient, identification of potential contraindications, and monitoring capacity if adverse reactions occur. Dr. Anthony C. Tam, MD — a sports medicine physician with Henry Ford Health and team physician for USA Wrestling, USA Cycling, and USA Volleyball — noted in an AMA interview: "It's always best to consult with a physician who can give you the best information and help you make the wisest decision. We want to find ways to improve your health in the safest ways possible."⁴

The BPC-157 + TB-500 stack: combined cost

Many buyers researching TB-500 are doing so in the context of the BPC-157 + TB-500 combination — sometimes called the "Wolverine stack." The cost picture for the stack is not simply additive.

• Research-vendor stack (both compounds): $60 to $200 per month for both compounds combined, with no clinical oversight. This combines two sources of sourcing uncertainty into a single protocol.
• Specialist clinic stack program: $300 to $900 per month, depending on program structure, which compounds are included, and monitoring frequency. Many clinics price the stack as a package protocol rather than two separate line items.
• Mid-tier clinic or med-spa stack: $200 to $500 per month, typically with less evaluation depth and lighter monitoring than specialist practices.

A common failure mode is buyers adding the individual compound costs together and assuming the stack is therefore the right choice. In clinical settings, some prescribing physicians recommend starting with a single compound and adding a second only if warranted — both because two simultaneous low-evidence compounds make outcomes harder to attribute, and because stack pricing is always higher than single-compound pricing. For the companion cost guide on BPC-157, see How Much Does BPC-157 Cost?.

TB-500 regulatory status affecting availability in 2026

Understanding what TB-500 costs through a licensed clinic requires understanding its regulatory position — which directly determines which pharmacies can legally compound and dispense it.

TB-500 (thymosin beta-4 fragment, LKKTETQ) was nominated for FDA Category 2 status under the 503A interim compounding policy. Category 2 designates substances for which the FDA has "identified significant safety risks relating to the use of these substances in compounding."¹ As of 2026, however, the FDA's own Category 2 page lists TB-500 under "Bulk drug substances nominated but withdrawn" — meaning the Category 2 nomination was withdrawn by the nominator, not that TB-500 has been approved for compounding or placed in Category 1. No formal Category 1 designation has been issued for TB-500.

The practical implication: the regulatory pathway for licensed pharmacy compounding of TB-500 is unsettled. Whether a specific 503A pharmacy can currently compound and dispense TB-500 depends on their interpretation of current FDA guidance, their state pharmacy board's requirements, and their risk tolerance as a practice. Anyone pursuing TB-500 through a licensed provider should verify current regulatory status directly with the prescribing physician and pharmacy at the time of consultation — not from secondary sources, including this page.

For the full regulatory framework covering peptide compounding, prescriptions, and legality, see our detailed guide to peptide legality and the FDA compounding framework.

Insurance, HSAs, and reimbursement

Health insurance does not cover TB-500. Medicare, Medicaid, and private insurance all require FDA drug approval for coverage, and TB-500 lacks that approval for any indication. There is no reimbursement pathway regardless of how you obtain it or who prescribes it.

Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs) may cover TB-500 costs when a licensed physician prescribes it for a qualifying medical condition. Whether that applies depends on the specific plan administrator, the nature of the prescription, and applicable tax-year rules. Verify this with your administrator and obtain an itemized invoice before assuming coverage.

Six-month total cost estimate

Buyers frequently underestimate the true cost of a supervised protocol by focusing on the per-vial or per-month medication price without accounting for the full clinical episode. A realistic six-month budget across the three main access pathways looks like this:

• Research-vendor path (six months): Compound costs of $120 to $600 depending on protocol and vendor, plus $20 to $60 in reconstitution supplies — total $140 to $660. No consultation, no monitoring, no accountability chain if something goes wrong.
• Mid-tier clinic or med-spa (six months): $0 to $150 initial consultation + $0 to $150 labs + $720 to $1,800 medication over six months + $0 to $450 in follow-up visits = $720 to $2,550, depending heavily on what the clinic includes in its monthly fee.
• Specialist clinic (six months): $150 to $400 initial consultation + $100 to $250 baseline labs + $1,050 to $2,700 medication over six months + $150 to $600 in monitoring visits = $1,450 to $3,950 all-in.

The lowest realistic cost for supervised care over six months — roughly $720 — is still 5× or more above the cheapest research-vendor sourcing. That premium reflects physician evaluation, pharmacy accountability, manufacturing standards, and an escalation path if adverse reactions occur. Whether that premium represents better value depends on your personal medical context, risk tolerance, and what you need from the protocol — not from a cost calculation alone.

Red flags in TB-500 pricing

The TB-500 market has enough legitimate options and enough low-quality operators that price alone is a poor quality signal in either direction. Several pricing patterns should prompt further questions:

• Research-vendor pricing below $4/mg: The fixed costs of solid-phase peptide synthesis, purification, lyophilization, and cold-chain logistics set a baseline below which meaningful quality assurance is difficult to maintain. Vendors offering significantly lower per-mg pricing typically reflect absent testing or quality controls.
• Clinic programs under $75/month: Legitimate clinical oversight in 2026 — including physician review, named pharmacy sourcing, and monitoring — cannot realistically be provided at near-vendor pricing. Low clinic prices typically describe minimal evaluation and no meaningful follow-up structure.
• Vague pharmacy sourcing: A clinic that cannot name the specific compounding pharmacy filling TB-500 prescriptions cannot demonstrate an accountable supply chain. This is a standard question worth asking before committing to any program.
• No requirement for prior evaluation: Any program willing to start someone on TB-500 without an intake evaluation or labs is running an access business rather than a clinical practice.

Comparison to the cost of alternatives

Patients exploring TB-500 often do so in the context of an injury recovery or tissue healing question. The cost comparison context matters:

• Physical therapy: $75 to $150 per session; typical recovery protocols involve 6 to 20 sessions ($450 to $3,000 total)
• Platelet-rich plasma (PRP) injections: $300 to $800 per injection; 3 to 5 treatments typically required ($900 to $4,000 total)
• Prolotherapy: $150 to $400 per session, multiple sessions required

On a pure dollar-per-month basis, TB-500 through a licensed clinic ($175 to $450 per month) sits below most regenerative medicine alternatives. Conventional alternatives like physical therapy, however, have well-established evidence bases and, in many cases, partial insurance coverage. TB-500 has neither. The cost comparison is useful context; so is the evidence comparison.

Questions to ask before you spend anything

If you are seriously considering TB-500 through a licensed provider, these questions are worth asking before committing to any program:

• Which pharmacy will dispense it, and what are their quality certifications? PCAB-accredited or 503B-registered facilities offer higher documented quality assurance than unaccredited 503A pharmacies.
• What does the quoted price actually include? Some clinics bundle consultation, follow-up visits, and supplies; others bill each separately. Get an itemized breakdown before any payment.
• Is TB-500 currently within FDA guidance for 503A compounding? Given regulatory flux, this is worth asking in writing at the time of your consultation.
• What does the clinic do if you have an adverse reaction at week three? Same-day response, 48-hour response, or a form to fill out — this distinction defines the value of the clinical premium.
• What would cause the clinic to modify or stop the protocol entirely? Clinics that answer this question are exercising clinical judgment; those that can't are selling access.

For a broader comparison of licensed telehealth clinics versus gray-market vendors across all peptides, see our guide to peptide telehealth vs. research vendors, which covers the full tradeoff in detail. For the broader question of what peptides typically cost across the full market, the peptide cost overview provides context across multiple compounds.

What this page cannot tell you

This guide covers pricing tiers and what drives the differences between them. It cannot tell you whether TB-500 is appropriate for your situation, whether the evidence base supports its use for your specific concern, or whether the regulatory environment will have shifted again by the time you read this. Those questions require a physician with access to your medical history and current regulatory guidance.

The cheapest TB-500 available online and the most expensive supervised specialist protocol represent a real tradeoff — not just in price, but in what you actually receive, what quality assurances exist, and what happens if something goes wrong. Understanding that tradeoff is more useful than any single number.